GBGisela Backfisch

Gisela Backfisch

*This is an algorithmically generated author record based on publicly available information.

Gisela Backfisch has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Frontispiece: Enzymatic Late‐Stage Oxidation of Lead Compounds with Solubilizing Biomimetic Docking/Protecting groups

    by Clare Vickers, Gisela Backfisch, Frank Oellien, Isabel Piel, Udo E. W. Lange

  • Enzymatic Late‐Stage Oxidation of Lead Compounds with Solubilizing Biomimetic Docking/Protecting groups

    by Clare Vickers, Gisela Backfisch, Frank Oellien, Isabel Piel, Udo E. W. Lange

    Late‐stage functionalization of lead compounds is of high interest in drug discovery since it offers an easy access to metabolites and derivatives of a lead compound without the need to redesign an often long multistep synthesis. Owing to their high degree of chemoselectivity, biocatalytic transformations, enzymatic oxidations in particular, are potentially very powerful because they could allow the synthesis of less lipophilic derivatives of a lead compound. In the majority of cases, enzymatic oxidations have been used in an empirical way as their regioselectivity is difficult to predict. In this publication, the concept of using docking/protecting groups in a biomimetic fashion was investigated, which could help steer the regioselectivity of a P450BM3‐mediated oxidation. A novel set of docking/protecting groups was designed that can be cleaved under very mild conditions and address the often problematic aqueous solubility of the substrates. Vabicaserin was used as tool compound containing typical groups such as basic, aliphatic, and aromatic moieties. The results were rationalized with the help of in silico docking and molecular dynamic studies.


  • Highly potent and selective αVβ3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones

    by Christian Zechel, Gisela Backfisch, Jürgen Delzer, Hervé Geneste, Claudia Graef, Wilfried Hornberger, Andreas Kling, Udo E.W Lange, Arnulf Lauterbach, Werner Seitz, et al.


  • Synthesis of highly potent and selective hetaryl ureas as integrin αVβ3-Receptor antagonists

    by Udo E.W. Lange, Gisela Backfisch, Jürgen Delzer, Hervé Geneste, Claudia Graef, Wilfried Hornberger, Andreas Kling, Arnulf Lauterbach, Thomas Subkowski, Christian Zechel


  • In vitro Studies of Poorly Absorbed Drugs Using Porcine Intestine in the Ring Model RIMO

    by Katja Nolte, Gisela Backfisch, Richard Neidlein

    Two compounds, an aminobisphosphonate (A) and a steroid (Β), showing a very large difference in lipophilicity (log PC (A) = O, log PC (B) > 8) but both revealing very poorly absorption in vivo of less than 1% were tested in respect of in vitro absorption and mucoadhesion using a model with porcine intestine named RIMO (ring model). Explanations for the poor absorption of the two compounds were investigated in order to propose methods for absorption enhancement. Moreover, absorption and mucoadhesion were measured for different parts of intestine with radiolabelled substances. Last but not least the inhibiting effect of calcium ions was investigated as well as enhancement by DTT (dithiothreitol), EDTA and bile. Results showed that mucus plays an important role in oral bioavailability. The aminobisphosphonate formed a complex with calcium ions which was insoluble in the mucus and resulted in a smaller amount of substance being absorbed. The very lipophilic steroid was kept back from the mucosa by the hydrophilic mucus, but addition of the solubilizer bile increased the absorption. The results were in good agreement with in vivo bioavailability data. Therefore, simplicity of the model and easy access of porcine intestine by slaughter houses make RIMO a valuable tool for investigations concerning the role of mucus and influences of diverse additives on absorption. In-vitro-Untersuchungen mit schlecht resorbierbaren Verbindungen unter Verwendung von Schweinedarm im Ringmodell RIMO Zwei in ihrer Lipophilie deutlich unterschiedliche Verbindungen, ein Aminobisphosphonat (A) und ein Steroid (B) (log PC (A) = 0, log PC (B) > 8), beide mit weniger als 1% In-vivo-Resorption, wurden hinsichtlich ihrer In-vitro-Resorption und Mukoadhäsion an einem Modell mit Schweinedarm (RIMO, Ring-Modell) untersucht. Um Möglichkeiten für eine Resorptionsverbesserung der beiden Verbindungen vorzuschlagen, wurden Erklärungen für ihre schlechte Resorption gesucht. Darüber hinaus wurden Resorption und Mukoadhäsion für verschiedene Darmabschnitte mit radioaktiv markierten Verbindungen untersucht. Der resorptionshemmende Einfluß von Calciumionen sowie Resorptionsförderern wie DTT (Dithiothreitol), EDTA und Galle wurden getestet. Es ergab sich, daß der Mukus für die orale Bioverfügbarkeit eine wichtige Rolle spielt. Das Aminobisphosphonat bildete mit Calciumionen einen Komplex, der im Mukus unlöslich war, was zu einer Abnahme der Resorption führte. Das sehr lipophile Steroid wurde durch den hydrophilen Mukus von der Mukosa zurückgehalten, aber der Zusatz des Lösungsvermittlers Galle erhöhte die Resorption. Die Ergebnisse bestätigten die in vivo erhaltenen Bioverfügbarkeitsdaten. Aufgrund der Einfachheit des Modells und der leichten Zugänglichkeit von Schweinedarm über den Schlachthof ist RIMO ein wertvolles Modell zur Untersuchung des Einflusses von Mukus und verschiedenen Additiven auf die Resorption.